Default company panoramic image

TheraBiol Inc

TheraBiol, Inc. was started in 2012 for developing safe and effective immune therapies to prevent, treat, and cure infectious diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded July 2012
  • Employees 3
  • Website

Company Summary

TheraBiol is devoted to developing antibody therapies for patients infected with HIV. The platform technologies for preparing immunogenic trimeric envelope glycoproteins subunits(TEGS) of newly transmitted HIV have been established. Monoclonal antibodies from mice immunized with TEGS will be genetically humanized for repeated treatment in the 5% of infected patients who fail long-term antiretroviral drugs and/or develop multi-system toxicities.


  • Default avatar
    Girish N Vyas

    Girish N. Vyas, Ph.D. is the Founder of TheraBiol Inc, and Professor of Laboratory Medicine at UCSF, where he established the Transfusion Medicine Program in 1980s. He has served on NIH, CDC, FDA, WHO and IABS Committees. He has published 225 papers and edited 12 books in the fields of transfusion safety, IgA deficiency, viral hepatitis and transfusion-transmitted infections. He is currently devoted to R&D of immune prophylaxis against HIV-1.

  • Default avatar
    MIchael Scott Killian
    Director of Research

    M. Scott Killian, Ph.D., MPH, serves as TBI’s Director of Research. He has seven years of HIV research experience at UCLA during his doctoral and Master’s degree in Public Health. For the past decade he conducted basic and translational research focused on HIV biology and pathogenesis in the UCSF Department of Medicine as a research scientist in Levy lab. His cumulative experience and accomplishments are ideally suited to TBI’s research goals.

  • Default avatar
    Evelin D Szakal
    Director of Corporate Development

    Evelin Szakal, Ph.D., is serving as a Senior Scientist and Director of Corporate development. Her 15 years of experience and expertise in biochemistry, quality assurance, and vaccine development are a major asset of TBI’s business plan. She earned her BS degree in Economics and Business and Ph.D. degree in Medical Virology. Her skillset will facilitate the development of products for clinical use.

  • Default avatar
    Mel Kronick
    Chief Business Advisor

    Mel Kronick, Ph.D., was President, CEO and Director of Population Genetics Technologies Ltd, Cambridge UK. In 2010 he returned to the US and continued to work as President and CEO until June 2011 when he transitioned to a role as Director and Consultant. He has over thirty years of experience in the life science tools industry including R&D management positions with Applied Biosystems and Agilent Technologies.

  • Default avatar
    Robert J. Pressley
    Chairman of the Board

    Robert Pressley, Ph.D., founded or co-founded five energy related companies, one IPO, two sold, and two still in business. From 1979-90 he served as the Founder and President of XMR, which was bought and incorporated into Amoco Technology Company. He was Co-Founder of Laserscope and served as Chairman of the Board (1984-2006); Laserscope was purchased in 2006 for $715,000,000. From 1991-1995 he was Co-Founder and CEO of Candescent Technologies.

  • Default avatar
    John Petricciani
    Member of the Board

    John Petricciani, M.D. was educated at Stanford Medical School and trained as a pediatrician. He was former Director of FDA Office of Biologics before moving to Geneva as Head of the WHO Biologicals Unit. He then served as the Vice President at the Genetics Institute in Boston and was Senior Vice President for Medical and Regulatory Affairs of Cancervax. He is now the President of the International Alliance for Biological Standardization.